

MEDIA RELEASE

Medical Developments International enters licensing agreement for Pentrox® (methoxyflurane) distribution with Ethypharm in France

Saint-Cloud, France & Melbourne, Australia – 29 April 2025. Medical Developments International (ASX: MVP) and Ethypharm have entered into a licensing agreement for marketing and distribution of Pentrox® (methoxyflurane) in France.

Pentrox® is an inhaled analgesic used across multiple countries for acute pain management. Under this agreement, Ethypharm will be responsible for the marketing and distribution of Pentrox® in France. Transition planning has commenced, with Ethypharm expected to commence its commercial activities in July 2025.

MVP's CEO Brent MacGregor said, *"Ethypharm's existing portfolio and market presence is complimentary to Pentrox®. Ethypharm is well positioned to support Pentrox® distribution in the hospital segment. We are excited to begin this relationship with Ethypharm to support access to Pentrox® for people in need in France."*

Xavier Lasserre, Chief Operating Officer of Ethypharm, added: *"At Ethypharm, we are committed to providing healthcare professionals with effective solutions for the treatment of moderate to severe acute traumatic pain. Partnering with Medical Developments International to support the distribution of Pentrox® in France aligns perfectly with our mission to deliver essential medicines that help improve patient lives. We look forward to a successful collaboration."*

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions, including pain relief and respiratory products, and is dedicated to improving patient outcomes. The Company manufactures Pentrox®, a non-opioid trauma & emergency pain relief product. It is approved in Australia for pain relief in settings such as hospitals, ambulance services and short procedures, in accordance with the approved Product Information.

About Ethypharm

Ethypharm is a leading mid-size international pharmaceutical company, with strong European roots, that manufactures and provides essential medicines, with a focus on Hospital Injectables and the Central Nervous System (severe pain and addiction).

Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment. Ethypharm has 1,800 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations. Our six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.

Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them.

To find out more about Ethypharm, visit <http://www.ethypharm.com>

Media Enquiries

Medical Developments International: info@medicaldev.com

Ethypharm: presse@ethypharm.com